Skip Navigation LinksTBCB-Branch-Publication-List

Tuberculosis Control branch

Published Studies

January 2000 through January 2024​

Publications by authors listing the California Tuberculosis Control Branch (TBCB) as their affiliation.

2024

  • Bertumen JB, Pascopella L, Han E, Glenn-Finer R, Wong RJ, Chitnis A, Jaganath D, Jewell M, Gounder P, McElroy S, Stockman L, Barry P. Epidemiology and Treatment Outcomes of Tuberculosis with Chronic Hepatitis B Infection-California, 2016-2020. Clin Infect Dis. 2024 Mar 26:ciae169. doi: 10.1093/cid/ciae169. Epub ahead of print. PMID: 38531668.
  • Miyakawa R, Louie J, Keh C, Chen L, Javid B, Ernst JD, Goswami N, Chow FC. A teenage girl with altered mental status and paraparesis. J Clin Tuberc Other Mycobact Dis. 2024 Mar 1;35:100425. doi: 10.1016/j.jctube.2024.100425. PMID: 38468819; PMCID: PMC10926304.
  • Ayers T, Hill AN, Raykin J, Mohanty S, Belknap RW, Brostrom R, Khurana R, Lauzardo M, Miller TL, Narita M, Pettit AC, Pyan A, Salcedo KL, Polony A, Flood J. Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease. JAMA Netw Open. 2024;7(4):e244769. doi:10.1001/jamanetworkopen.2024.4769
  • Nabity SA, Agraz-Lara R, Bravo A, et al. Notes from the Field: Supply Interruptions of First- and Second-Line Oral Drugs to Treat Tuberculosis During the Previous 12 Months — California, January–March, 2023. MMWR Morb Mortal Wkly Rep 2024;72:1390–1391.
  • Han E, Nabity SA, Dasgupta-Tsinikas S, Guevara RE, Moore M, Kadakia A, et al. Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020. Emerg Infect Dis, 2024.​

2023​

  • Han E, Nabity SA, Dasgupta-Tsinikas S, Guevara RE, Moore M, Kadakia A, et al. Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020. Emerg Infect Dis. 2024;30(1):136-140. https://doi.org/10.3201/eid3001.230924
  • Katrak S, Wang R, Barry P. Costs of treating multidrug-resistant TB in California in 2022. Int J Tuberc Lung Dis. 2023 Nov 1;27(11):864-866. doi: 10.5588/ijtld.23.0150. PMID: 37880888; PMCID: PMC10599414.
  • Frazier C, Nabity SA, Flood J. Incidence of TB Disease among persons who use drugs in California. The International Journal of Tuberculosis of Lung Disease, 2023.
  • Nabity SA, Marks SM, Goswami ND, Smith SR, Timme E, Price SF, Gross L, Self JL, Toren KG, Narita M, Wegener DH, Wang S. Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States. Emerging Infectious Diseases, 2023.
  • Louie JK, Keh CE. Latent Tuberculosis Infection Treatment: Still a Long Road Ahead, Clinical Infectious Diseases, 2023.
  • Shete PB, Tang AS, Flood J. Screening for Latent Tuberculosis Infection Among Non-US-Born Adults in the US A Path toward Elimination. Journal of the American Medical Association, 2023.
  • Tang AS, Mochizuki T, Dong Z, Flood J, Katrak S. Can Primary Care Drive Tuberculosis Elimination? Increasing Latent Tuberculosis Infection Testing and Treatment Initiation at a Community Health Center with a Large Non-U.S.-born Population. J Immigrant Minority Health, 2023.​
Page Last Updated :